Your email has been successfully added to our mailing list.

×
0.000782013685239475 0.00195503421309862 0.000977517106549309 0.000195503421309834 -0.00332355816226787 -0.00410557184750735 -0.00332355816226787 -0.00449657869012715
Stock impact report

Cytokinetics to get up to $575M in funding from Royalty Pharma [Seeking Alpha]

Cytokinetics, Incorporated (CYTK) 
Last cytokinetics, incorporated earnings: 3/3 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.cytokinetics.com/investor-overview
Company Research Source: Seeking Alpha
upfront, to support commercialization of Cytokinetics' drug aficamten and advancement of its pipeline. Under the deal, Cytokinetics will receive $50M for the commercial launch Recommended For You More Trending News Recommended For You More Trending News Show less Read more
Impact Snapshot
Event Time:
CYTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for CYTK alerts
Opt-in for
CYTK alerts

from News Quantified
Opt-in for
CYTK alerts

from News Quantified